Cargando…

Evaluation of Ferric and Ferrous Iron Therapies in Women with Iron Deficiency Anaemia

Introduction. Different ferric and ferrous iron preparations can be used as oral iron supplements. Our aim was to compare the effects of oral ferric and ferrous iron therapies in women with iron deficiency anaemia. Methods. The present study included 104 women diagnosed with iron deficiency anaemia...

Descripción completa

Detalles Bibliográficos
Autores principales: Berber, Ilhami, Diri, Halit, Erkurt, Mehmet Ali, Aydogdu, Ismet, Kaya, Emin, Kuku, Irfan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4071784/
https://www.ncbi.nlm.nih.gov/pubmed/25006339
http://dx.doi.org/10.1155/2014/297057
_version_ 1782322856102723584
author Berber, Ilhami
Diri, Halit
Erkurt, Mehmet Ali
Aydogdu, Ismet
Kaya, Emin
Kuku, Irfan
author_facet Berber, Ilhami
Diri, Halit
Erkurt, Mehmet Ali
Aydogdu, Ismet
Kaya, Emin
Kuku, Irfan
author_sort Berber, Ilhami
collection PubMed
description Introduction. Different ferric and ferrous iron preparations can be used as oral iron supplements. Our aim was to compare the effects of oral ferric and ferrous iron therapies in women with iron deficiency anaemia. Methods. The present study included 104 women diagnosed with iron deficiency anaemia after evaluation. In the evaluations performed to detect the aetiology underlying the iron deficiency anaemia, it was found and treated. After the detection of the iron deficiency anaemia aetiology and treatment of the underlying aetiology, the ferric group consisted of 30 patients treated with oral ferric protein succinylate tablets (2 × 40 mg elemental iron/day), and the second group consisted of 34 patients treated with oral ferrous glycine sulphate tablets (2 × 40 mg elemental iron/day) for three months. In all patients, the following laboratory evaluations were performed before beginning treatment and after treatment. Results. The mean haemoglobin and haematocrit increases were 0.95 g/dL and 2.62% in the ferric group, while they were 2.25 g/dL and 5.91% in the ferrous group, respectively. A significant difference was found between the groups regarding the increase in haemoglobin and haematocrit values (P < 0.05). Conclusion. Data are submitted on the good tolerability, higher efficacy, and lower cost of the ferrous preparation used in our study.
format Online
Article
Text
id pubmed-4071784
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-40717842014-07-08 Evaluation of Ferric and Ferrous Iron Therapies in Women with Iron Deficiency Anaemia Berber, Ilhami Diri, Halit Erkurt, Mehmet Ali Aydogdu, Ismet Kaya, Emin Kuku, Irfan Adv Hematol Clinical Study Introduction. Different ferric and ferrous iron preparations can be used as oral iron supplements. Our aim was to compare the effects of oral ferric and ferrous iron therapies in women with iron deficiency anaemia. Methods. The present study included 104 women diagnosed with iron deficiency anaemia after evaluation. In the evaluations performed to detect the aetiology underlying the iron deficiency anaemia, it was found and treated. After the detection of the iron deficiency anaemia aetiology and treatment of the underlying aetiology, the ferric group consisted of 30 patients treated with oral ferric protein succinylate tablets (2 × 40 mg elemental iron/day), and the second group consisted of 34 patients treated with oral ferrous glycine sulphate tablets (2 × 40 mg elemental iron/day) for three months. In all patients, the following laboratory evaluations were performed before beginning treatment and after treatment. Results. The mean haemoglobin and haematocrit increases were 0.95 g/dL and 2.62% in the ferric group, while they were 2.25 g/dL and 5.91% in the ferrous group, respectively. A significant difference was found between the groups regarding the increase in haemoglobin and haematocrit values (P < 0.05). Conclusion. Data are submitted on the good tolerability, higher efficacy, and lower cost of the ferrous preparation used in our study. Hindawi Publishing Corporation 2014 2014-06-11 /pmc/articles/PMC4071784/ /pubmed/25006339 http://dx.doi.org/10.1155/2014/297057 Text en Copyright © 2014 Ilhami Berber et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Berber, Ilhami
Diri, Halit
Erkurt, Mehmet Ali
Aydogdu, Ismet
Kaya, Emin
Kuku, Irfan
Evaluation of Ferric and Ferrous Iron Therapies in Women with Iron Deficiency Anaemia
title Evaluation of Ferric and Ferrous Iron Therapies in Women with Iron Deficiency Anaemia
title_full Evaluation of Ferric and Ferrous Iron Therapies in Women with Iron Deficiency Anaemia
title_fullStr Evaluation of Ferric and Ferrous Iron Therapies in Women with Iron Deficiency Anaemia
title_full_unstemmed Evaluation of Ferric and Ferrous Iron Therapies in Women with Iron Deficiency Anaemia
title_short Evaluation of Ferric and Ferrous Iron Therapies in Women with Iron Deficiency Anaemia
title_sort evaluation of ferric and ferrous iron therapies in women with iron deficiency anaemia
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4071784/
https://www.ncbi.nlm.nih.gov/pubmed/25006339
http://dx.doi.org/10.1155/2014/297057
work_keys_str_mv AT berberilhami evaluationofferricandferrousirontherapiesinwomenwithirondeficiencyanaemia
AT dirihalit evaluationofferricandferrousirontherapiesinwomenwithirondeficiencyanaemia
AT erkurtmehmetali evaluationofferricandferrousirontherapiesinwomenwithirondeficiencyanaemia
AT aydogduismet evaluationofferricandferrousirontherapiesinwomenwithirondeficiencyanaemia
AT kayaemin evaluationofferricandferrousirontherapiesinwomenwithirondeficiencyanaemia
AT kukuirfan evaluationofferricandferrousirontherapiesinwomenwithirondeficiencyanaemia